Modelling the costs and benefits of an mRNA compared to a DNA high-risk HPV assay in a hypothetical HPV primary screening algorithm in Ontario, Canada

Cases of cervical cancer in Canada have decreased recently as a result of cytology-based screening programs. However, cervical cancer remains a relatively common and preventable cause of cancer in women. As cervical cancer is primarily caused by persistent genital infection with high-risk (HR) human papillomaviruses, Ontario Health has been evaluating implementing HPV-based testing in cervical screening.

As the type of HR-HPV test used in a cervical screen program can impact costs and resources, Aquarius Population Health developed a decision tree model to compare the use of the Aptima mRNA HR-HPV assay to a DNA HR-HPV assay in a hypothetical HPV primary screening algorithm in Ontario, Canada.

Results found for women aged 30-65 years screened in Ontario, using an mRNA versus a DNA HR-HPV assay would save over $4M CAD and avoid roughly 11,000 unnecessary colposcopies, 15,000 HPV tests and 40,000 cytology tests.

Continue reading

Is it cost effective to screen women for syphilis twice during pregnancy?

The UK National Screening Committee (UK NSC) asked Aquarius to assess the costs and benefits of two different approaches to antenatal screening for syphilis.

We compared the current strategy – screening in the first trimester only – with an alternative strategy – screening in the first trimester and a repeat screen later in pregnancy.  The results of our cost-effectiveness analysis were recently published in BMJ Open and are now available online.

Continue reading